UnitedHealth Group's unexpected CEO replacement and 2025 guidance withdrawal reflect rising Medicare Advantage costs and market uncertainty, impacting stock performance and investor confidence.

UnitedHealth downgraded to Neutral by BofA after suspending 2025 guidance due to Medicare Advantage challenges. Analyst price targets and ratings vary amid uncertainty.

Elevance Health lowers full-year profit forecast despite Q1 revenue growth driven by higher premiums and membership gains in Medicare Advantage and ACA.